Retrospective Review on the Use of Topical Cyclosporin A 0.05% for Paediatric Allergic Conjunctivitis in Hong Kong Chinese

Abstract EN

Purpose.

To evaluate the efficacy of using topical cyclosporin A 0.05% (Restasis) for the treatment of paediatric allergic conjunctivitis.

Methods.

This retrospective study included consecutive cases of paediatric allergic conjunctivitis treated with Restasis between 2010 and 2013.

Subjects with follow-up time less than 3 months after using Restasis were excluded.

Itch severity score, symptom score, and sign score were compared before (baseline) and 3 months after using Restasis.

Results.

In 27 eyes of 14 patients (mean age 10.8 ± 3.2 years), 44.4% had allergic conjunctivitis, 33.3% had vernal keratoconjunctivitis, and 22.2% had atopic keratoconjunctivitis.

The mean duration of ocular symptoms was 20.4 ± 13.2 months.

92.6% of subjects were using steroid eye drop before Restasis.

After 3 months of topical Restasis, there were statistically significant reductions in the symptom, sign, and itch severity scores compared with baseline (all P ≤ 0.001 ) and 78.6% of subjects were able to be tapered off steroid eye drops.

Conclusion.

Topical Restasis was effective and safe in significantly reducing ocular itchiness, sign, and symptom scores at 3 months after use in paediatric allergic ocular conditions.